Massive Bio Continues to Grow in Europe

Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B investments received in the first half of this year, Massive Bio announced the hiring of three new team members who will help expand the company's global operations, intensify its marketing activities, develop new data sets and products, and expand its M&A efforts. The new recruits are Toygun Onaran, who will serve as Head of Strategy; Mert Sarı, who will be Regional Manager; and Sinan Fındık, who comes on board as Clinical Research and Data Manager. "The current changes we are making today will help us better reach and support more cancer patients in the future" Massive Bio's expanding presence in Europe will allow the company to continue its mission of ensuring that all cancer patients receive treatment under fair and favorable conditions, said Çağlar Demirbağ, Director of International Partnerships, which manages the company's operations outside of the United States, adding that "there are about 4 million patients diagnosed with cancer annually in Europe. With the steps we have taken in the last two years, we have been ensuring that thousands of cancer patients in Spain, Italy, France, Germany, Romania, Poland, and Greece are matched to appropriate clinical trials. This is also enabling that these patients receive the best treatment free of charge."